Novo GlucaGen Launch For Hypoglycemia Awaits Co-Marketing Agreement
Executive Summary
Novo Nordisk will launch its recombinant DNA glucagon product GlucaGen only after it has found a co-marketing partner, the company said following approval June 22.
You may also be interested in...
Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer
FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011